Akili, Inc.

DNAA, a special purpose acquisition company focused on the digital health and healthcare technology sector, filed an 8-K with the Securities and Exchange Commission on January 26, 2022, under accession number 0001193125-22-017656, in connection with its announced business combination with Akili, Inc. Akili is a prescription digital therapeutics company developing software-based cognitive health treatments, representing a then-emerging category within the broader digital medicine industry. The filing captures the SPAC at an active deal stage, with the transaction drawing attention to the intersection of consumer technology and regulated healthcare. For the complete filing record, deal timeline, sponsor details, and comparable SPAC transactions across digital health, sign up for full data on SpacDesk.